Live: Will FedEx Crush Q4 Earnings Tonight After the Market Closes?
WST Q3 2025 Earnings
Reported Oct 23, 2025 at 7:15 AM ET · SEC Source
Q3 25 EPS
$1.96
BEAT +16.31%
Est. $1.69
Q3 25 Revenue
$804.6M
BEAT +2.15%
Est. $787.7M
vs S&P Since Q3 25
-0.3%
TRAILING MARKET
WST +8.9% vs S&P +9.2%
Market Reaction
Did WST Beat Earnings? Q3 2025 Results
West Pharmaceutical Services posted a standout third quarter, with adjusted diluted EPS of $1.96 beating the $1.69 consensus estimate by 15.98% as surging demand for GLP-1 drug delivery components lifted results well above expectations. Net sales cli… Read more West Pharmaceutical Services posted a standout third quarter, with adjusted diluted EPS of $1.96 beating the $1.69 consensus estimate by 15.98% as surging demand for GLP-1 drug delivery components lifted results well above expectations. Net sales climbed 7.7% year-over-year to $804.60 million, anchored by a 16.3% jump in High-Value Product Components to $390.00 million, driven by elastomers tied to obesity and diabetes therapies and Annex 1 regulatory conversion activity. GLP-1-related products accounted for a combined 17% of total company revenues in the quarter, underscoring how meaningfully that end market has reshaped West's revenue mix. Gross margin expanded 120 basis points to 36.6%, reflecting the favorable shift toward higher-margin HVP products. Management responded to the momentum by raising full-year 2025 net sales guidance to $3.06 billion–$3.07 billion and meaningfully lifting adjusted EPS guidance to $7.06–$7.11, from a prior range of $6.65–$6.85. The results drew fresh analyst attention, with at least one coverage initiation citing West's positioning in injectable biologics and GLP-1 as a basis for sustained revenue and margin expansion ahead.
Key Takeaways
- • Double-digit growth in HVP Components driven by GLP-1 products, Annex 1 conversions, and improving demand environment
- • GLP-1 elastomers represented 9% of total company revenues in Q3
- • GLP-1 Contract Manufacturing revenues represented 8% of total company revenues in Q3
- • Biologics market group accounted for 41% of revenue, growing 11.0% YoY
- • Annex 1 regulatory conversions tracking ahead of expectations, driving approximately 200 bps of FY25 sales growth
- • Gross margin expanded 120 bps to 36.6% driven by favorable product mix shift to HVP
- • Contract Manufacturing growth driven by self-injection devices for obesity and diabetes
WST YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
WST Revenue by Segment
With YoY comparisons, source: SEC Filings
WST Revenue by Geography
With YoY comparisons, source: SEC Filings
“I am pleased to report that we delivered another solid quarter, with both revenues and profits exceeding our guidance. Our strength was broad-based, across both our Proprietary Products and Contract Manufacturing segments. We achieved double-digit growth in our HVP Components business, driven by our continued execution in GLP-1 products, increased HVP conversion, including Annex 1, and an overall improving demand environment. As a result of the solid performance in the quarter, and the ongoing momentum in our business, we are again increasing our full-year guidance expectations.”
— Eric M. Green, Q3 2025 Earnings Press Release
WST Earnings Trends
WST vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
WST EPS Trend
Earnings per share: estimate vs actual
WST Revenue Trend
Quarterly revenue: estimate vs actual
WST Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.68 | $2.13 | +27.07% | $844.9M | +8.41% |
| Q4 25 BEAT FY | $1.83 | $2.04 | +11.54% | $805.0M | +1.28% |
| FY Full Year | — | $7.29 | — | $3.07B | — |
| Q3 25 BEAT | $1.69 | $1.96 | +16.31% | $804.6M | +2.15% |
| Q2 25 BEAT | $1.51 | $1.84 | +21.98% | $766.5M | +5.55% |